Catalyst Pharmaceutical (CPRX) reported $148.39 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 15.3%. EPS of $0.68 for the same period compares to $0.57 a year ago.
The reported revenue represents a surprise of +8.77% over the Zacks Consensus Estimate of $136.43 million. With the consensus EPS estimate being $0.51, the EPS surprise was +33.33%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product revenue, Net- FIRDAPSE: $92.18 million versus the four-analyst average estimate of $91.78 million. The reported number represents a year-over-year change of +16.2%.
- Revenues- Product revenue, Net- FYCOMPA: $23.8 million versus $15.16 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -25.8% change.
- Revenues- Product revenue, Net- AGAMREE: $32.38 million versus the four-analyst average estimate of $29.47 million. The reported number represents a year-over-year change of +115.2%.
- Revenues- Product revenue,net: $148.37 million versus the four-analyst average estimate of $136.41 million. The reported number represents a year-over-year change of +17.4%.
- Revenues- License and other: $0.03 million versus the three-analyst average estimate of $0.02 million.
View all Key Company Metrics for Catalyst here>>>
Shares of Catalyst have returned +2.5% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
